Bufuralol (BioDeep_00000009568)
Secondary id: BioDeep_00001871524
human metabolite blood metabolite
代谢物信息卡片
2-(tert-butylamino)-1-(7-ethyl-1-benzofuran-2-yl)ethan-1-ol
化学式: C16H23NO2 (261.1728698)
中文名称: 丁呋洛尔
谱图信息:
最多检出来源 Homo sapiens(blood) 98.7%
分子结构信息
SMILES: CCC1=CC=CC2=C1OC(=C2)C(CNC(C)(C)C)O
InChI: InChI=1S/C16H23NO2/c1-5-11-7-6-8-12-9-14(19-15(11)12)13(18)10-17-16(2,3)4/h6-9,13,17-18H,5,10H2,1-4H3
描述信息
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists
Bufuralol (Ro 3-4787) is a potent non-selective, orally active β-adrenoreceptor antagonist with partial agonist activity. Bufuralol hydrochloride is a CYP2D6 probe substrate[1][2][3][4].
同义名列表
数据库引用编号
15 个数据库交叉引用编号
- ChEBI: CHEBI:34593
- KEGG: C13769
- PubChem: 71733
- HMDB: HMDB0249434
- Metlin: METLIN69695
- DrugBank: DB06726
- ChEMBL: CHEMBL296035
- Wikipedia: Bufuralol
- chemspider: 64777
- CAS: 54340-62-4
- CAS: 57704-15-1
- PMhub: MS000023361
- PubChem: 7846930
- NIKKAJI: J12.455I
- medchemexpress: HY-105124
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Jie Cai, Da-Peng Dai, Pei-Wu Geng, Shuang-Hu Wang, Hao Wang, Yun-Yun Zhan, Xiang-Xin Huang, Guo-Xin Hu, Jian-Ping Cai. Effects of 22 Novel CYP2D6 Variants Found in the Chinese Population on the Bufuralol and Dextromethorphan Metabolisms In Vitro.
Basic & clinical pharmacology & toxicology.
2016 Mar; 118(3):190-9. doi:
10.1111/bcpt.12478. [PMID: 26310775] - Colin J Henderson, Lesley A McLaughlin, Nico Scheer, Lesley A Stanley, C Roland Wolf. Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo.
Molecular pharmacology.
2015 Apr; 87(4):733-9. doi:
10.1124/mol.114.097394. [PMID: 25657337] - Xiaochun Zhu, Yuping Chen, Raju Subramanian. Comparison of information-dependent acquisition, SWATH, and MS(All) techniques in metabolite identification study employing ultrahigh-performance liquid chromatography-quadrupole time-of-flight mass spectrometry.
Analytical chemistry.
2014 Jan; 86(2):1202-9. doi:
10.1021/ac403385y. [PMID: 24383719] - Cho-Ming Loi, Dennis A Smith, Deepak Dalvie. Which metabolites circulate?.
Drug metabolism and disposition: the biological fate of chemicals.
2013 May; 41(5):933-51. doi:
10.1124/dmd.112.050278. [PMID: 23454828] - Evangelos P Daskalopoulos, Matti A Lang, Marios Marselos, Foteini Malliou, Maria Konstandi. D₂-dopaminergic receptor-linked pathways: critical regulators of CYP3A, CYP2C, and CYP2D.
Molecular pharmacology.
2012 Oct; 82(4):668-78. doi:
10.1124/mol.112.078709. [PMID: 22772593] - Sui-Lin Mo, Wei-Feng Liu, Chun-Guang Li, Zhi-Wei Zhou, Hai-Bin Luo, Helen Chew, Jun Liang, Shu-Feng Zhou. Pharmacophore, QSAR, and binding mode studies of substrates of human cytochrome P450 2D6 (CYP2D6) using molecular docking and virtual mutations and an application to chinese herbal medicine screening.
Current pharmaceutical biotechnology.
2012 Jul; 13(9):1640-704. doi:
10.2174/138920112800958779. [PMID: 22039821] - Jialin Mao, Michael A Mohutsky, John P Harrelson, Steven A Wrighton, Stephen D Hall. Predictions of cytochrome P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions.
Drug metabolism and disposition: the biological fate of chemicals.
2012 Apr; 40(4):706-16. doi:
10.1124/dmd.111.043158. [PMID: 22228749] - Hua Cai, Jun Jiang, Qi Yang, Qingmei Chen, Yiqun Deng. Functional characterization of a first avian cytochrome P450 of the CYP2D subfamily (CYP2D49).
PloS one.
2012; 7(6):e38395. doi:
10.1371/journal.pone.0038395. [PMID: 22675558] - Jacob Kramer Jacobsen, Bente Jensen, Christian Skonberg, Steen Honoré Hansen, Lassina Badolo. Time-course activities of Oct1, Mrp3, and cytochrome P450s in cultures of cryopreserved rat hepatocytes.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
2011 Oct; 44(3):427-36. doi:
10.1016/j.ejps.2011.09.001. [PMID: 21925601] - Toshiro Niwa, Norie Murayama, Hiromi Umeyama, Makiko Shimizu, Hiroshi Yamazaki. Human liver enzymes responsible for metabolic elimination of tyramine; a vasopressor agent from daily food.
Drug metabolism letters.
2011 Aug; 5(3):216-9. doi:
10.2174/187231211796905026. [PMID: 21679153] - Nina Nordman, Tiina Sikanen, Maria-Elisa Moilanen, Susanna Aura, Tapio Kotiaho, Sami Franssila, Risto Kostiainen. Rapid and sensitive drug metabolism studies by SU-8 microchip capillary electrophoresis-electrospray ionization mass spectrometry.
Journal of chromatography. A.
2011 Feb; 1218(5):739-45. doi:
10.1016/j.chroma.2010.12.010. [PMID: 21185563] - Anna M Wobus, Peter Löser. Present state and future perspectives of using pluripotent stem cells in toxicology research.
Archives of toxicology.
2011 Feb; 85(2):79-117. doi:
10.1007/s00204-010-0641-6. [PMID: 21225242] - Timo Korjamo, Ari Tolonen, Veli-Pekka Ranta, Miia Turpeinen, Hannu Kokki. Metabolism of oxycodone in human hepatocytes from different age groups and prediction of hepatic plasma clearance.
Frontiers in pharmacology.
2011; 2(?):87. doi:
10.3389/fphar.2011.00087. [PMID: 22291644] - Shan Wang, Shuo Yang, Baiyi An, Shichen Wang, Yuejia Yin, Yang Lu, Ying Xu, Dongyun Hao. Molecular dynamics analysis reveals structural insights into mechanism of nicotine N-demethylation catalyzed by tobacco cytochrome P450 mono-oxygenase.
PloS one.
2011; 6(8):e23342. doi:
10.1371/journal.pone.0023342. [PMID: 21858078] - Hiroshi Yamazaki, Kana Horiuchi, Ryohji Takano, Taku Nagano, Makiko Shimizu, Masato Kitajima, Norie Murayama, Fumiaki Shono. Human blood concentrations of cotinine, a biomonitoring marker for tobacco smoke, extrapolated from nicotine metabolism in rats and humans and physiologically based pharmacokinetic modeling.
International journal of environmental research and public health.
2010 09; 7(9):3406-21. doi:
10.3390/ijerph7093406. [PMID: 20948932] - Manthena V S Varma, Bo Feng, R Scott Obach, Matthew D Troutman, Jonathan Chupka, Howard R Miller, Ayman El-Kattan. Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry.
2009 Aug; 52(15):4844-52. doi:
10.1021/jm900403j. [PMID: 19445515] - Robert D Finn, Lesley A McLaughlin, Sebastien Ronseaux, Ian Rosewell, J Brian Houston, Colin J Henderson, C Roland Wolf. Defining the in Vivo Role for cytochrome b5 in cytochrome P450 function through the conditional hepatic deletion of microsomal cytochrome b5.
The Journal of biological chemistry.
2008 Nov; 283(46):31385-93. doi:
10.1074/jbc.m803496200. [PMID: 18805792] - R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals.
2008 Jul; 36(7):1385-405. doi:
10.1124/dmd.108.020479. [PMID: 18426954] - Dermot F McGinnity, Nigel J Waters, James Tucker, Robert J Riley. Integrated in vitro analysis for the in vivo prediction of cytochrome P450-mediated drug-drug interactions.
Drug metabolism and disposition: the biological fate of chemicals.
2008 Jun; 36(6):1126-34. doi:
10.1124/dmd.108.020446. [PMID: 18356267] - Mohamed M Hefnawy, Maha A Sultan, Mona M Al-Shehri. HPLC separation technique for analysis of bufuralol enantiomers in plasma and pharmaceutical formulations using a vancomycin chiral stationary phase and UV detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2007 Sep; 856(1-2):328-36. doi:
10.1016/j.jchromb.2007.06.021. [PMID: 17681871] - Akio Nakamura, Katsuhiko Tougou, Hiroko Kitazumi, Tetsuhiro Yamada, Kumikto Honjou, Kiyoko Nonaka, Hideya Mukai. Effects of irsogladine on P450-isoform specific activities in human hepatic microsomes.
Arzneimittel-Forschung.
2006; 56(7):547-52. doi:
10.1055/s-0031-1296750. [PMID: 16927538] - Robert S Foti, Michael B Fisher. Impact of incubation conditions on bufuralol human clearance predictions: enzyme lability and nonspecific binding.
Drug metabolism and disposition: the biological fate of chemicals.
2004 Mar; 32(3):295-304. doi:
10.1124/dmd.32.3.295. [PMID: 14977863] - John-Michael Sauer, Amanda J Long, Barbara Ring, Jennifer S Gillespie, Nathan P Sanburn, Karl A DeSante, David Petullo, Mark R VandenBranden, Charles B Jensen, Steven A Wrighton, Brian P Smith, Holly A Read, Jennifer W Witcher. Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome.
The Journal of pharmacology and experimental therapeutics.
2004 Feb; 308(2):410-8. doi:
10.1124/jpet.103.058727. [PMID: 14610241] - Parnali Chatterjee, Michael R Franklin. Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components.
Drug metabolism and disposition: the biological fate of chemicals.
2003 Nov; 31(11):1391-7. doi:
10.1124/dmd.31.11.1391. [PMID: 14570772] - Roman Zuber, Martin Modrianský, Zdenek Dvorák, Petr Rohovský, Jitka Ulrichová, Vilím Simánek, Pavel Anzenbacher. Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities.
Phytotherapy research : PTR.
2002 Nov; 16(7):632-8. doi:
10.1002/ptr.1000. [PMID: 12410543] - Nu He, Wen-Qi Zhang, Dolores Shockley, Timi Edeki. Inhibitory effects of H1-antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomes.
European journal of clinical pharmacology.
2002 Feb; 57(12):847-51. doi:
10.1007/s00228-001-0399-0. [PMID: 11936702] - A Juhász, N Bodor. Cardiovascular studies on different classes of soft drugs.
Die Pharmazie.
2000 Mar; 55(3):228-38. doi:
. [PMID: 10756546] - S K Paulson, L Engel, B Reitz, S Bolten, E G Burton, T J Maziasz, B Yan, G L Schoenhard. Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib.
Drug metabolism and disposition: the biological fate of chemicals.
1999 Oct; 27(10):1133-42. doi:
NULL. [PMID: 10497139] - S Ikegawa, K Matsuura, T Sato, N M Isriyanthi, T Niwa, S Miyairi, H Takashina, Y Kawashima, J Goto. Enantioselective immunoaffinity extraction for simultaneous determination of optically active bufuralol and its metabolites in human plasma by HPLC.
Journal of pharmaceutical and biomedical analysis.
1998 May; 17(1):1-9. doi:
10.1016/s0731-7085(97)00147-7. [PMID: 9608420] - K Nakamura, T Yokoi, K Inoue, N Shimada, N Ohashi, T Kume, T Kamataki. CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes.
Pharmacogenetics.
1996 Oct; 6(5):449-57. doi:
10.1097/00008571-199610000-00009. [PMID: 8946477] - Q Jiang, Y Huang, J M Voigt, B K DeBolt, S Kominami, S Takemori, Y Funae, H D Colby. Expression and zonal distribution of CYP2D16 in the guinea pig adrenal cortex: relationship to xenobiotic metabolism.
Molecular pharmacology.
1996 Mar; 49(3):458-64. doi:
. [PMID: 8643085] - W E Haefeli, M J Bargetzi, F Follath, U A Meyer. Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo.
Journal of cardiovascular pharmacology.
1990 May; 15(5):776-9. doi:
10.1097/00005344-199005000-00013. [PMID: 1692938] - H K Kroemer, G Mikus, T Kronbach, U A Meyer, M Eichelbaum. In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone.
Clinical pharmacology and therapeutics.
1989 Jan; 45(1):28-33. doi:
10.1038/clpt.1989.5. [PMID: 2910635] - E J Lee, S Moochhala. Tissue distribution of bufuralol hydroxylase activity in Sprague-Dawley rats.
Life sciences.
1989; 44(13):827-30. doi:
10.1016/0024-3205(89)90582-1. [PMID: 2927246] - U M Zanger, H P Hauri, J Loeper, J C Homberg, U A Meyer. Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II.
Proceedings of the National Academy of Sciences of the United States of America.
1988 Nov; 85(21):8256-60. doi:
10.1073/pnas.85.21.8256. [PMID: 3186722] - T H Pringle, R J Francis, P B East, R G Shanks. Pharmacodynamic and pharmacokinetic studies on bufuralol in man.
British journal of clinical pharmacology.
1986 Nov; 22(5):527-34. doi:
10.1111/j.1365-2125.1986.tb02931.x. [PMID: 2878678] - M S Lennard, G T Tucker, H F Woods. The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.
Clinical pharmacokinetics.
1986 Jan; 11(1):1-17. doi:
10.2165/00003088-198611010-00001. [PMID: 2868819] - P Dayer, T Leemann, A Küpfer, T Kronbach, U A Meyer. Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation.
European journal of clinical pharmacology.
1986; 31(3):313-8. doi:
10.1007/bf00981130. [PMID: 2878813] - A Wellstein, D Palm, J H Matthews, G G Belz. In vitro receptor occupancy allows to establish equieffective doses of beta-blockers with different pharmacodynamic profiles in man. Investigations with propranolol and bufuralol.
Methods and findings in experimental and clinical pharmacology.
1985 Dec; 7(12):645-51. doi:
. [PMID: 3007897] - M S Lennard. Oxidation phenotype and the metabolism and action of beta-blockers.
Klinische Wochenschrift.
1985 Apr; 63(7):285-92. doi:
10.1007/bf01731972. [PMID: 2860267] - R L Smith. Polymorphic metabolism of the beta-adrenoreceptor blocking drugs and its clinical relevance.
European journal of clinical pharmacology.
1985; 28 Suppl(?):77-84. doi:
10.1007/bf00543715. [PMID: 2865154] - P Dayer, A Suenram, D Pometta, J Fabre. Apparent lack of influence of the genetic drug oxidation status on plasma cholesterol concentration in man.
Pharmacological research communications.
1984 Feb; 16(2):129-34. doi:
10.1016/s0031-6989(84)80087-9. [PMID: 6504965] - L Balant. Applicability of different types of models in health and disease.
Drug metabolism reviews.
1984; 15(1-2):75-102. doi:
10.3109/03602538409015058. [PMID: 6378564] - J H Silas, M S Lennard, G T Tucker, L E Ramsay, H F Woods. Polymorphic metabolism of beta-adrenoceptor antagonists.
British journal of clinical pharmacology.
1984; 17 Suppl 1(?):11S-19S. doi:
10.1111/j.1365-2125.1984.tb02423.x. [PMID: 6146335] - B Truniger, G Bischoff, T Schmidli. [Bufuralol: do beta blockers reduce blood circulation in the kidneys?].
Schweizerische medizinische Wochenschrift.
1983 Sep; 113(37):1331-3. doi:
. [PMID: 6138856] - P Dayer, F Courvoisier, A Kupfer, A Balant-Gorgia, L Balant, J Fabre. [Pharmacokinetic and clinical consequences of the genetic polymorphism of oxidation].
Schweizerische medizinische Wochenschrift.
1983 Feb; 113(8):295-7. doi:
NULL. [PMID: 6133350] - L P Balant, P Dayer, J Fabre. Consequences of renal insufficiency on the hepatic clearance of some drugs.
International journal of clinical pharmacology research.
1983; 3(6):459-74. doi:
. [PMID: 6147317] - P Dayer, L Balant, A Küpfer, F Courvoisier, J Fabre. Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents.
European journal of clinical pharmacology.
1983; 24(6):797-9. doi:
10.1007/bf00607090. [PMID: 6136413] - P Dayer, L Balant, J Fabre. The genetic control of drug oxidation in the liver.
International journal of clinical pharmacology research.
1983; 3(6):421-5. doi:
NULL. [PMID: 6147316] - P Dayer, L Balant, F Courvoisier, A Kupfer, A Kubli, A Gorgia, J Fabre. The genetic control of bufuralol metabolism in man.
European journal of drug metabolism and pharmacokinetics.
1982 Jan; 7(1):73-7. doi:
10.1007/bf03189547. [PMID: 6121708] - R J Francis, P B East, J Larman. Kinetics and metabolism of (+)-, (-)- and (+/-)-bufuralol.
European journal of clinical pharmacology.
1982; 23(6):529-33. doi:
10.1007/bf00637501. [PMID: 6130953] - P Haefelfinger. Determination of bufuralol and its major metabolites in plasma by high-performance liquid chromatography.
Journal of chromatography.
1980 Dec; 221(2):327-35. doi:
10.1016/s0378-4347(00)84318-2. [PMID: 7217302] - L Balant, R J Francis, T N Tozer, A Marmy, J M Tschopp, J Fabre. Influence of renal failure on the hepatic clearance of bufuralol in man.
Journal of pharmacokinetics and biopharmaceutics.
1980 Oct; 8(5):421-38. doi:
10.1007/bf01059544. [PMID: 6114166] - J M Tschopp, A Gorgia, L Balant, C Revillard, R J Francis, F J Fabre. [Role of metabolites in the relationship between pharmacokinetics and the effect of beta blockers. Studies on tolamolol and bufuralol].
Schweizerische medizinische Wochenschrift.
1978 May; 108(20):756-64. doi:
NULL. [PMID: 26114] - A Rostan. [Effects of tolamolol and bufuralol on the arterial blood pressure and plasma renin activity. Contribution to the study of beta-blocking agents action mechanisms (author's transl)].
Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis.
1978 Jan; 67(1):27-35. doi:
. [PMID: 23523] - R J Francis, P B East, S J McLaren, J Larman. Determined of bufuralol and its metabolites in plasma by mass fragmentography and by gas chromatography with electron capture detection.
Biomedical mass spectrometry.
1976 Dec; 3(6):281-5. doi:
10.1002/bms.1200030606. [PMID: 1000058] - P Weidmann, C Beretta-Piccoli, W Ziegler, D Hirsch, R D de Châtel, F C Reubi. [Interrelations between blood pressure, blood volume, plasma renin and urinary catecholamines during beta-blockade in essential hypertension (author's transl)].
Klinische Wochenschrift.
1976 Aug; 54(16):765-73. doi:
10.1007/bf01614293. [PMID: 8663] - J A de Silva, J C Meyer, C V Puglisi. Spectrofluorometric determination of bufuralol in blood and urine.
Journal of pharmaceutical sciences.
1976 Aug; 65(8):1230-33. doi:
10.1002/jps.2600650825. [PMID: 10418]